These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38645297)

  • 21. Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
    Gatti M; Andreoni M; Pea F; Viale P
    Drug Des Devel Ther; 2021; 15():3349-3378. PubMed ID: 34376971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality.
    de Pablo-Miró M; Pujol-Ruiz S; Iftimie S; Arenas-Miras MDM; López-Montesinos I; Duran-Jordà X; Anglès A; Grau S; Horcajada JP
    Antibiotics (Basel); 2021 Oct; 10(11):. PubMed ID: 34827234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness, safety and cost analysis of dalbavancin in clinical practice.
    Arrieta-Loitegui M; Caro-Teller JM; Ortiz-Pérez S; López-Medrano F; San Juan-Garrido R; Ferrari-Piquero JM
    Eur J Hosp Pharm; 2022 Jan; 29(1):55-58. PubMed ID: 33020060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple-Dose Dalbavancin Regimens as the Predominant Treatment of Deep-Seated or Endovascular Infections: A Scoping Review.
    Cooper MM; Preslaski CR; Shihadeh KC; Hawkins KL; Jenkins TC
    Open Forum Infect Dis; 2021 Nov; 8(11):ofab486. PubMed ID: 34738025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin.
    Cho JC; Estrada SJ; Beltran AJ; Revuelta MP
    J Clin Pharm Ther; 2015 Oct; 40(5):604-606. PubMed ID: 26183753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-World Data Regarding Dalbavancin Use before and during the COVID-19 Pandemic-A Single-Center Retrospective Study.
    Ioannou P; Wolff N; Mathioudaki A; Spanias C; Spernovasilis N; Kofteridis DP
    Antibiotics (Basel); 2023 Jul; 12(7):. PubMed ID: 37508301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. REDS study: Retrospective effectiveness study of dalbavancin and other standard of care of the same IV antibiotic class in patients with ABSSSI.
    Papavramidis T; Gentile I; Cattelan AM; Magnasco L; Viale P; Francisci D; Kofteridis DP; Tiseo G; Giamarellos-Bourboulis EJ; Lagi F; Pinna SM; D'Amico F; La Ferla L; Panagopoulos P; Gattuso G; Sipsas NV; Ruggieri A; Cattaneo A; Corio L; Comandini A; Mascagni P; Bassetti M
    Int J Antimicrob Agents; 2023 Apr; 61(4):106746. PubMed ID: 36758778
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Use of Dalbavancin for Treatment of Soft Tissue and Bone Infection in Children: Safe, Effective and Hospital-Time Sparing.
    Caselli D; Mariani M; Colomba C; Ferrecchi C; Cafagno C; Trotta D; Carloni I; Dibello D; Castagnola E; Aricò M
    Children (Basel); 2024 Jan; 11(1):. PubMed ID: 38255391
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Substance use disorder-associated infections' treatment with dalbavancin enabling outpatient transition (SUDDEN OUT) - an investigator-initiated single-arm unblinded prospective cohort study.
    Krsak M; Scherger S; Miller MA; Cobb V; Montague BT; Henao-Martínez AF; Molina KC
    Ther Adv Infect Dis; 2024; 11():20499361231223889. PubMed ID: 38249543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials.
    Gonzalez PL; Rappo U; Akinapelli K; McGregor JS; Puttagunta S; Dunne MW
    Infect Dis Ther; 2022 Feb; 11(1):423-434. PubMed ID: 34905144
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of outpatient parenteral antimicrobial therapy (OPAT) for patients with cranial infection.
    Kilinc F; Setzer M; Behmanesh B; Jussen D; Gessler F; Bayerl S; Kempf VAJ; Kessel J; Czabanka M; Prinz V
    Front Med (Lausanne); 2023; 10():1202969. PubMed ID: 37942421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience with dalbavancin for long-term antimicrobial suppression of left ventricular assist device infections.
    Mansoor AE; Krekel T; Cabrera NL
    Transpl Infect Dis; 2023 Aug; 25(4):e14068. PubMed ID: 37159539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful use of dalbavancin in the treatment of gram positive blood stream infections: a case series.
    Evins C; Lancaster H; Schnee AE
    Ann Clin Microbiol Antimicrob; 2022 Apr; 21(1):16. PubMed ID: 35473711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical experience with dalbavancin for the treatment of deep sternal wound infection.
    Bartoletti M; Mikus E; Pascale R; Giannella M; Tedeschi S; Calvi S; Tenti E; Tumietto F; Viale P
    J Glob Antimicrob Resist; 2019 Sep; 18():195-198. PubMed ID: 30926464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dalbavancin in Gram-positive periprosthetic joint infections.
    Simon S; Frank BJH; Hartmann S; Hinterhuber L; Reitsamer M; Aichmair A; Dominkus M; Söderquist B; Hofstaetter JG
    J Antimicrob Chemother; 2022 Jul; 77(8):2274-2277. PubMed ID: 35678452
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of dalbavancin in skin and soft tissue infections.
    Bassetti M; Peghin M; Carnelutti A; Righi E
    Curr Opin Infect Dis; 2018 Apr; 31(2):141-147. PubMed ID: 29298166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A retrospective analysis of adverse events among patients receiving daptomycin versus vancomycin during outpatient parenteral antimicrobial therapy.
    Schrank GM; Wright SB; Branch-Elliman W; LaSalvia MT
    Infect Control Hosp Epidemiol; 2018 Aug; 39(8):947-954. PubMed ID: 29893658
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT; Tsuji BT
    Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.
    Esposito S; Pagliano P; De Simone G; Guarino A; Pan A; Brambilla P; Mastroianni C; Lichtner M; Brugnaro P; Carretta A; Santantonio T; Brindicci G; Carrega G; Montagnani F; Lapadula G; Spolti A; Luzzati R; Schiaroli E; Scaglione V; Pallotto C; Tacconi D; Quintieri F; Trecarichi E;
    Infection; 2024 Feb; ():. PubMed ID: 38324144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.
    Tobudic S; Forstner C; Burgmann H; Lagler H; Steininger C; Traby L; Vossen MG; Winkler S; Thalhammer F
    Infection; 2019 Dec; 47(6):1013-1020. PubMed ID: 31520397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.